Informações:
Falhas:
ID
21406
Descrição
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes; ODM derived from: https://clinicaltrials.gov/show/NCT00454480
Link
https://clinicaltrials.gov/show/NCT00454480
Palavras-chave
Versões (1)
- 19/04/2017 19/04/2017 -
Transferido a
19 de abril de 2017
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Leukemia NCT00454480
Eligibility Leukemia NCT00454480
- StudyEvent: Eligibility
Similar models
Eligibility Leukemia NCT00454480
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Diagnosis
Item
diagnosis of 1 of the following:
boolean
C0011900 (UMLS CUI [1])
Leukemia, Myelocytic, Acute
Item
acute myeloid leukemia (aml) meeting the following criteria:
boolean
C0023467 (UMLS CUI [1])
Acute Myelocytic Leukemia de novo | secondary acute myeloid leukemia
Item
de novo or secondary aml
boolean
C0023467 (UMLS CUI [1,1])
C1515568 (UMLS CUI [1,2])
C0280449 (UMLS CUI [2])
C1515568 (UMLS CUI [1,2])
C0280449 (UMLS CUI [2])
Acute Promyelocytic Leukemia Absent
Item
no acute promyelocytic leukemia
boolean
C0023487 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,2])
MYELODYSPLASTIC SYNDROME High risk | Bone marrow Blasts Percentage | Refractory anemia with excess blasts II
Item
high-risk myelodysplastic syndromes (> 10% marrow blasts; refractory anemia with excess blasts-2)
boolean
C3463824 (UMLS CUI [1,1])
C0332167 (UMLS CUI [1,2])
C1982687 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C1318551 (UMLS CUI [3])
C0332167 (UMLS CUI [1,2])
C1982687 (UMLS CUI [2,1])
C0439165 (UMLS CUI [2,2])
C1318551 (UMLS CUI [3])
Chronic Myeloid Leukemia Blast transformation Absent
Item
no blast transformation of chronic myeloid leukemia
boolean
C0023473 (UMLS CUI [1,1])
C0024262 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
C0024262 (UMLS CUI [1,2])
C0332197 (UMLS CUI [1,3])
Age | Unfit Clinical Trial specified
Item
patients ≤ 60 years of age may be eligible provided they are considered unfit for clinical trial mrc-amli5
boolean
C0001779 (UMLS CUI [1])
C3841806 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C0205369 (UMLS CUI [2,3])
C3841806 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
C0205369 (UMLS CUI [2,3])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
not pregnant or nursing
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Gemtuzumab ozogamicin
Item
ast and alt ≤ 2 times upper limit of normal (uln) (for patients receiving gemtuzumab ozogamicin)
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C1533699 (UMLS CUI [3])
C0201836 (UMLS CUI [2])
C1533699 (UMLS CUI [3])
Serum total bilirubin measurement | Gemtuzumab ozogamicin
Item
bilirubin ≤ 2 times uln (for patients receiving gemtuzumab ozogamicin)
boolean
C1278039 (UMLS CUI [1])
C1533699 (UMLS CUI [2])
C1533699 (UMLS CUI [2])
Serum creatinine normal | clofarabine
Item
creatinine normal (for patients receiving clofarabine)
boolean
C0438244 (UMLS CUI [1])
C0092777 (UMLS CUI [2])
C0092777 (UMLS CUI [2])
Malignant Neoplasm | Basal cell carcinoma
Item
no other concurrent active malignancy except basal cell carcinoma
boolean
C0006826 (UMLS CUI [1])
C0007117 (UMLS CUI [2])
C0007117 (UMLS CUI [2])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Cytotoxic Chemotherapy Acute Myelocytic Leukemia
Item
no prior cytotoxic chemotherapy for aml
boolean
C0677881 (UMLS CUI [1,1])
C0023467 (UMLS CUI [1,2])
C0023467 (UMLS CUI [1,2])
hydroxyurea | Low-Dose Treatment Similar | White Blood Cell Count | Initiation Therapeutic procedure Intensity
Item
hydroxyurea or similar low-dose therapy to control wbc count prior to initiation of intensive therapy allowed
boolean
C0020402 (UMLS CUI [1])
C1708745 (UMLS CUI [2,1])
C2348205 (UMLS CUI [2,2])
C0023508 (UMLS CUI [3])
C1704686 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C0522510 (UMLS CUI [4,3])
C1708745 (UMLS CUI [2,1])
C2348205 (UMLS CUI [2,2])
C0023508 (UMLS CUI [3])
C1704686 (UMLS CUI [4,1])
C0087111 (UMLS CUI [4,2])
C0522510 (UMLS CUI [4,3])
Anticonvulsants Enzyme Induction | Phenytoin | Phenobarbital | Primidone | Carbamazepine | oxcarbazepine | tipifarnib
Item
no concurrent enzyme anticonvulsants, including phenytoin, phenobarbital, primidone, carbamazepine, or oxcarbazepine (for patients receiving tipifarnib)
boolean
C0003286 (UMLS CUI [1,1])
C0014431 (UMLS CUI [1,2])
C0031507 (UMLS CUI [2])
C0031412 (UMLS CUI [3])
C0033148 (UMLS CUI [4])
C0006949 (UMLS CUI [5])
C0069751 (UMLS CUI [6])
C1176289 (UMLS CUI [7])
C0014431 (UMLS CUI [1,2])
C0031507 (UMLS CUI [2])
C0031412 (UMLS CUI [3])
C0033148 (UMLS CUI [4])
C0006949 (UMLS CUI [5])
C0069751 (UMLS CUI [6])
C1176289 (UMLS CUI [7])
Sem comentários